Trials / Completed
CompletedNCT02900157
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MEDI9090 | MEDI9090 will be administered by IV infusion |
| BIOLOGICAL | Durvalumab | Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090. |
Timeline
- Start date
- 2016-08-09
- Primary completion
- 2020-01-23
- Completion
- 2020-01-23
- First posted
- 2016-09-14
- Last updated
- 2021-01-14
Locations
8 sites across 2 countries: United States, Japan
Source: ClinicalTrials.gov record NCT02900157. Inclusion in this directory is not an endorsement.